{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:44:54Z","timestamp":1791996294038,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Kynurenic acid (KYNA) is an <jats:sc>l<\/jats:sc>-tryptophan metabolite with neuromodulatory activities, regulating the release of neurotransmitters such as glutamate, dopamine (DA), and acetylcholine (Ach). Dysregulation of the kynurenine pathway has been associated with neurodegenerative, neurological, and psychological disorders such as Alzheimer\u2019s disease, Parkinson\u2019s disease,\u00a0Huntington\u2019s disease, major depressive disorder, and schizophrenia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The antidepressant-like effects of KYNA were studied with a modified mouse forced swimming test (FST), and the potential involvement of the serotonin (SER), norepinephrine, DA, Ach, <jats:italic>N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate, or gamma-aminobutyric acid subunit A (GABA<jats:sub>A<\/jats:sub>) receptors in its antidepressant-like effect was assayed by modified combination mouse FST. In combination studies, the mice were pretreated with the respective receptor antagonist, cyproheptadine (CPH), phenoxybenzamine, yohimbine, propranolol, haloperidol (HPD), atropine, MK-801, or bicuculline (BCL).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The FST revealed that KYNA reversed immobility, climbing, and swimming times, suggesting the antidepressant-like effects of KYNA. Furthermore, the combination studies showed that CPH prevented the antidepressant-like effects of\u00a0KYNA on immobility, climbing, and swimming times, whereas HPD reduced climbing time and BCL influenced immobility and climbing times and prevented the effects of KYNA on swimming time.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The results demonstrated, for the first time, the presence of antidepressant-like effects of\u00a0KYNA in a modified mouse FST. Furthermore, modified combination FST showed that the antidepressant-like actions of KYNA strongly interacted with 5-hydroxytryptamine type 2\u00a0SER-ergic receptors, weakly interacted with D<jats:sub>2<\/jats:sub>, D<jats:sub>3<\/jats:sub>, D<jats:sub>4<\/jats:sub> DA-ergic receptors, and interacted moderately with GABA<jats:sub>A<\/jats:sub> receptors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s43440-020-00067-5","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T02:02:53Z","timestamp":1583978573000},"page":"449-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Antidepressant-like effects of kynurenic acid in a modified forced swim test"],"prefix":"10.1007","volume":"72","author":[{"given":"Masaru","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Boh\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di\u00e1na","family":"Martos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Telegdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"4","key":"67_CR1","first-page":"239","volume":"14","author":"I Plangar","year":"2012","unstructured":"Plangar I, Majlath Z, Vecsei L. Kynurenines in cognitive functions: their possible role in depression. Neuropsychopharmacol Hung. 2012;14(4):239\u201344.","journal-title":"Neuropsychopharmacol Hung"},{"issue":"1","key":"67_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrd3793","volume":"12","author":"L V\u00e9csei","year":"2013","unstructured":"V\u00e9csei L, Szal\u00e1rdy L, F\u00fcl\u00f6p F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12(1):64\u201382.","journal-title":"Nat Rev Drug Discov"},{"key":"67_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbi.2015.11.003","volume":"53","author":"TB Meier","year":"2016","unstructured":"Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, et al. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav Immun. 2016;53:39\u201348.","journal-title":"Brain Behav Immun"},{"key":"67_CR4","volume-title":"Stereotaxic atlas of the rat brain","author":"AS Pellegrino","year":"1979","unstructured":"Pellegrino AS, Cushman AJ. Stereotaxic atlas of the rat brain. New York: Plenum Press; 1979."},{"issue":"1","key":"67_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0091-3057(00)00300-2","volume":"67","author":"RT Khisti","year":"2000","unstructured":"Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav. 2000;67(1):137\u201343.","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"67_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0028-1094391","volume":"6","author":"IP Lapin","year":"1973","unstructured":"Lapin IP. Kynurenines as probable participants of depression. Pharmakopsychiatr Neuropsychopharmakol. 1973;6(6):273\u20139.","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"issue":"1","key":"67_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0091-3057(90)90043-H","volume":"37","author":"L V\u00e9csei","year":"1990","unstructured":"V\u00e9csei L, Beal MF. Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. Pharmacol Biochem Behav. 1990;37(1):71\u20136.","journal-title":"Pharmacol Biochem Behav"},{"key":"67_CR8","first-page":"56","volume":"47","author":"GF Oxenkrug","year":"2010","unstructured":"Oxenkrug GF. Tryptophan\u2013kynurenine metabolism as a common mediator of genetic and environmental Impacts in major depressive disorder: The serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci. 2010;47:56\u201363.","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"2","key":"67_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00702-011-0681-y","volume":"119","author":"Y M\u00e1ndi","year":"2012","unstructured":"M\u00e1ndi Y, V\u00e9csei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna). 2012;119(2):197\u2013209.","journal-title":"J Neural Transm (Vienna)"},{"key":"67_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fendo.2019.00158","volume":"10","author":"E H\u00f6glund","year":"2019","unstructured":"H\u00f6glund E, \u00d8verli \u00d8, Winberg S. Tryptophan Metabolic pathways and brain serotonergic activity: a comparative review. Front Endocrinol (Lausanne). 2019;10:158.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"67_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/bmb\/lds004","volume":"101","author":"E Palazidou","year":"2012","unstructured":"Palazidou E. The neurobiology of depression. Br Med Bull. 2012;101:127\u201345.","journal-title":"Br Med Bull"},{"key":"67_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fphar.2012.00195","volume":"3","author":"TL Schwartz","year":"2012","unstructured":"Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 2012;3:195.","journal-title":"Front Pharmacol"},{"key":"67_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0278-5846(01)00222-6","volume":"26","author":"ML Kram","year":"2002","unstructured":"Kram ML, Kramer GL, Ronan PJ, Steciuk M, Petty F. Dopamine receptors and learned helplessness in the rat: an autoradiographic study. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:639\u201345.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"67_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","volume":"185","author":"R Trullas","year":"1990","unstructured":"Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185:1\u201310.","journal-title":"Eur J Pharmacol"},{"key":"67_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0022-3956(88)90001-5","volume":"22","author":"A Honig","year":"1988","unstructured":"Honig A, Bartlett JR, Bouras N, Bridges PK. Amino acid levels in depression: a preliminary investigation. J Psychiatr Res. 1988;22:159\u201364.","journal-title":"J Psychiatr Res"},{"key":"67_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0006-3223(02)01449-X","volume":"53","author":"JP Herman","year":"2003","unstructured":"Herman JP, Renda A, Bodie B. Norepinephrine-gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: effects of reboxetine on GABAergic neurons. Biol Psychiatry. 2003;53:166\u201374.","journal-title":"Biol Psychiatry"},{"key":"67_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1176\/appi.ajp.159.4.663","volume":"159","author":"G Sanacora","year":"2002","unstructured":"Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663\u20135.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"67_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","volume":"16","author":"B Luscher","year":"2011","unstructured":"Luscher B, Shen Q, Sahir N. The GABAergic Deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383\u2013406.","journal-title":"Mol Psychiatry"},{"key":"67_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/75761","volume":"3","author":"RM McKernan","year":"2000","unstructured":"McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587\u201392.","journal-title":"Nat Neurosci"},{"key":"67_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neubiorev.2018.03.023","volume":"90","author":"K Ogyu","year":"2018","unstructured":"Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16\u201325.","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00067-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-020-00067-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00067-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:27:59Z","timestamp":1615508879000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-020-00067-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00067-5","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest regarding this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}